An early improvement threshold to predict response and remission in first-episode schizophrenia

British Journal of Psychiatry

Volumn 196, Issue 6, 2010, Pages 460-466

  Schennach Wolff, Rebecca ^a   Seemuller F H ^a   Mayr, A ^a   Maier, W ^b   Klingberg, S ^c   Heuser, I ^d   Klosterkotter J ^e   Gastpar, M ^f   Hafner H ^g   Sauer, H ^h   Schneider, F ⁱ   Gaebel, W ^j   Jager M ^k   Moller H J ^k   Riedel, M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f Fliedner Klinik   (Germany)

^g CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^h FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

ⁱ RWTH AACHEN UNIVERSITY   (Germany)

^j HEINRICH HEINE UNIVERSITY   (Germany)

^k Department of Psychiatry ^*  (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BIPERIDEN; HALOPERIDOL; LORAZEPAM; PROPRANOLOL; RISPERIDONE;

ADULT; AGED; AKATHISIA; ANXIETY DISORDER; ARTICLE; CONSENSUS; DRUG DOSE INCREASE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTIVE VALIDITY; REMISSION; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GERMANY; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; REMISSION INDUCTION; RISPERIDONE; ROC CURVE; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952995920     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.109.069328     Document Type: Article

References (34)

1. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003; 60: 1228-1235 (Pubitemid 37494076)
2. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane J. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003; 160: 2063-2065 (Pubitemid 39619650)
3. Leucht S, Shamsi SA, Busch R, Kissling W, Kane JM. Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study. Schizophr Res 2008; 101: 312-319
4. Lin CH, Chou LS, Lin CH, Hsu CY, Chen YS, Lane HY. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. J Clin Psychiatry 2007; 68: 1522-1527
5. Kasper S. First-episode schizophrenia: the importance of early intervention and subjective tolerability. J Clin Psychiatry 1999; 60 (suppl 23): 5-9.
6. Emsley R, Oosthuizen PP, Kidd M, Koen L, Niehaus DJ, Turner HJ. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J Clin Psychiatry 2006; 67: 1707-1712
7. Emsley R, Rabinowitz J, Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res 2007; 89: 129-139 (Pubitemid 44881311)
8. Crespo-Facorro B, Pelayo-Teran JM, Perez-Iglesias R, Ramírez- Bonilla M, Martínez-García O, Pardo-García G, et al. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J Psychiatr Res 2007; 41: 659-666
9. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005; 162: 947-953
10. Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, von Wilmsdorff M, et al. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 2007; 68: 1763-1774
11. Möller HJ, Riedel M, Jäger M, Wickelmaier F, Maier W, Kühn KU, et al. Shortterm treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol 2008; 11: 985-997
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). APA, 1994.
13. Cording C. Conceptual aspects in development and implementation of basic psychiatric documentation [in German]. Psychiatr Prax 1998; 25: 175-178
14. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988; 23: 99-110.
15. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub. (ADM). National Institute for Mental Health, 1976.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM-III-R). APA, 1987.
17. Kinon BJ, Chen L, Scher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 2008; 102: 230-240
18. Obermeier M, Mayr A, Schennach-Wolff R, Seemüller F, Möller HJ, Riedel M. Should the PANSS be rescaled? Schizophr Bull 2009; [epub ahead of print].
19. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441-449
20. Weinstein MC, Fineberg HV. Clinical Decisions Analysis. Saunders, 1980.
21. Fawcett T. An introduction to ROC analysis. Pattern Recognit Lett 2006; 27: 861-874
22. R Development Core Team. A Language and Environment for Statistical Computing. Foundation for Statistical Computing, 2008 (http//:www.R-project.org) .
23. Cumming G. Inference by eye: reading the overlap of independent confidence intervals. Stat Med 2009; 28: 205-220
24. McCreadie RG. Managing the first episode of schizophrenia: the role of new therapies. Eur Neuropsychopharmacol 1996; 6 (suppl 2): S3-5.
25. Chang YC, Lane HY, Yang KH, Huang CL. Optimizing early prediction for antipsychotic response in schizophrenia. J Clin Psychopharmacol 2006; 26: 554-559
26. Leucht S, Busch R, Kissling W, Kane M. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry 2007; 68: 352-360
27. Ceskova E, Prikryl R, Kasparek T, Ondrusova M. Psychopathology and treatment responsiveness of patients with first-episode schizophrenia. Neuropsychiatr Dis Treat 2005; 1: 179-185
28. Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res 2009; 115: 97-103.
29. Crespo-Facorro B, Perez-Iglesias R, Ramirez-Bonilla M, Martínez-García O, Llorca J, Luis Vázquez-Barquero J. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of firstepisode nonaffective psychosis. J Clin Psychiatry 2006; 67: 1511-1521
30. Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 1999; 25: 721-729
31. Efron B, Tibshirani R. An Introduction to the Bootstrap. Monographs on Statistics and Applied Probability 57. Chapman & Hall/CRC, 1994.
32. Scher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull 2008; 34: 1163-1171
33. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry 2006; 163: 743-745
34. Jäger M, Schmauß M, Laux G, Pfeiffer H, Naber D, Schmidt LG, et al. Early improvement as a predictor of remission and response in schizophrenia. Results from a naturalistic study. Eur Psychiatry 2009; 24: 501-506